Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072395 | 0.95 | LMNA (0.32) | KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL6072303 | 0.92 | KDM4E (0.33) | KDM4EALDH1A1LMNAMAPTSSTR5 | |
| SCHEMBL6072045 | 0.86 | LTB4R2 (0.33) | KDM4EALDH1A1LMNAMAPTSSTR5 | |
| SCHEMBL6072251 | 0.86 | IRAK4 (0.30) | — | |
| SCHEMBL6072516 | 0.86 | MAPT (0.33) | KDM4EALDH1A1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL6072382 | 0.86 | — | — | |
| SCHEMBL6071895 | 0.85 | TDP1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL6072954 | 0.85 | MCL1 (0.41) | KDM4EALDH1A1LMNAMAPTADRB1 | |
| SCHEMBL6208625 | 0.85 | KDM4E (0.32) | KDM4EALDH1A1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL6071838 | 0.84 | TDP1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | KDM4E 358/4885ALDH1A1 423/4885LMNA 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.